Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMPARISON OF IDARUBICIN TO DAUNOMYCIN IN A RANDOMIZED MULTIDRUG TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA AT FIRST BONE-MARROW RELAPSE - A REPORT FROM THE CHILDRENS CANCER GROUP
Autore:
FEIG SA; AMES MM; SATHER HN; STEINHERZ L; REID JM; TRIGG M; PENDERGRASS TW; WARKENTIN P; GERBER M; LEONARD M; BLEYER WA; HARRIS RE;
Indirizzi:
CHILDRENS CANC GRP,POB 60012 ARCADIA CA 91066 UNIV CALIF LOS ANGELES,MED CTR LOS ANGELES CA 90024 UNIV SO CALIF,SCH MED LOS ANGELES CA 00000 MAYO CLIN & MAYO FDN ROCHESTER MN 55905 MEM SLOAN KETTERING CANC CTR NEW YORK NY 10021 UNIV IOWA HOSP & CLIN IOWA CITY IA 52242 CHILDRENS HOSP & MED CTR SEATTLE WA 98105 UNIV NEBRASKA,MED CTR OMAHA NE 00000 PHARMACIA ADRIA COLUMBUS OH 00000 CHILDRENS HOSP MED CTR CINCINNATI OH 00000 UNIV MICHIGAN,CS MOTT CHILDRENS HOSP ANN ARBOR MI 48109 UNIV TEXAS,MD ANDERSON CANC CTR HOUSTON TX 00000
Titolo Testata:
Medical and pediatric oncology
fascicolo: 6, volume: 27, anno: 1996,
pagine: 505 - 514
SICI:
0098-1532(1996)27:6<505:COITDI>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOGENOUS LEUKEMIA; DOSE CYTOSINE-ARABINOSIDE; PEDIATRIC-ONCOLOGY-GROUP; 2ND REMISSION; COMBINATION CHEMOTHERAPY; LYMPHOCYTIC-LEUKEMIA; SUBSEQUENT REMISSION; INTENSIVE THERAPY; ADULT PATIENTS; TRANSPLANTATION;
Keywords:
IDARUBICIN; DAUNOMYCIN; CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
43
Recensione:
Indirizzi per estratti:
Citazione:
S.A. Feig et al., "COMPARISON OF IDARUBICIN TO DAUNOMYCIN IN A RANDOMIZED MULTIDRUG TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA AT FIRST BONE-MARROW RELAPSE - A REPORT FROM THE CHILDRENS CANCER GROUP", Medical and pediatric oncology, 27(6), 1996, pp. 505-514

Abstract

The outcome of children with acute lymphoblastic leukemia (ALL) and bone marrow relapse has been unsatisfactory largely because of failure to prevent subsequent leukemia relapses. Ninety-six patients were enrolled and received vincristine, prednisone, L-asparaginase, and an anthracycline as reinduction therapy. Ninety-two patients were randomized to receive either daunomycin (DNR) or idarubicin (IDR). After achievement of second complete remission (CR2), maintenance chemotherapy included the same anthracycline, IDR or DNR high-dose cytarabine, and escalating-dose methotrexate. Compared to DNR (45 mg/m(2)/week x 3), IDR (12.5 mg/m(2)/week x 3) was associated with prolonged myelosuppression and more frequent serious infections. Halfway through the study, the dose of IDR was reduced to 10 mg/m(2). Overall, second remission was achieved in 71% of patients. Reinduction rate was similar for IDR and DNR. Reasons for induction failure differed; none of 15, 1 of 5, and 5 of7 reinduction failures were due to infection for DNR, IDR (10 mg/m(2)), and IDR (12.5 mg/m(2)), respectively. Two-year event-free survival (EFS) was better among patients who received IDR (12.5 mg/m(2)) (27 +/- 18%) compared to DNR (10 +/- 8%, P=0.05) and IDR (10 mg/m(2)) (6 +/-12%, P=0.02). However, after 3 years of follow-up, late events in thehigh-dose IDR group result in a similar EFS to the lower-dose IDR andDNR groups. In conclusion, IDR is an effective agent in childhood ALL. When used weekly at 12.5 mg/m(2) during induction, the EFS outcome during the first 2 years of treatment appears better than lower-dose IDR or DNR (45 mg/m(2)), although this difference was not sustained at longer periods of follow-up. Increased hematopoietic toxicity seen at this dose might be reduced through the use of supportive measures, suchas hematopoietins and intestinal decontamination. (C) 1996 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 05:42:50